Silencing of CDK5 as potential therapy for Alzheimer's disease.

Silencing of CDK5 as potential therapy for Alzheimer's disease.

Item
http://www.wikidata.org/entity/Q37863144
p120-catenin is necessary for neuroprotection induced by CDK5 silencing in models of Alzheimer's diseaseProtection after stroke: cellular effectors of neurovascular unit integrity.Molecular mechanisms of environmental enrichment: impairments in Akt/GSK3β, neurotrophin-3 and CREB signaling.Tolfenamic acid reduces tau and CDK5 levels: implications for dementia and tauopathies.The Ambiguous Relationship of Oxidative Stress, Tau Hyperphosphorylation, and Autophagy Dysfunction in Alzheimer's Disease.A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice.Special Issue on "Cdk5 and Brain Disorders": PrologueOxidative Stress and Aberrant Cell Cycle in Alzheimer's Disease Lymphocytes: Diagnostic Prospects.Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal.
P2860

Silencing of CDK5 as potential therapy for Alzheimer's disease.

Item
http://www.wikidata.org/entity/Q37863144
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Silencing of CDK5 as potential therapy for Alzheimer's disease.
@en
Silencing of CDK5 as potential therapy for Alzheimer's disease.
@nl
type
label
Silencing of CDK5 as potential therapy for Alzheimer's disease.
@en
Silencing of CDK5 as potential therapy for Alzheimer's disease.
@nl
prefLabel
Silencing of CDK5 as potential therapy for Alzheimer's disease.
@en
Silencing of CDK5 as potential therapy for Alzheimer's disease.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P921
P356
P1433
P1476
Silencing of CDK5 as potential therapy for Alzheimer's disease.
@en
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P921